Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. [PubChem] (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| - Distribution half-life is 7 to 12 minutes. Elimination half-life is 33 to 110 minutes. (en)
|
http://linked.open...ugbank/indication
| - For the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Edrophonium works by prolonging the action acetylcholine, which is found naturally in the body. It does this by inhibiting the action of the enzyme acetylcholinesterase. Acetylcholine stimulates nicotinic and muscarinic receptors. When stimulated, these receptors have a range of effects. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...outeOfElimination
| - Edrophonium is primarily renally excreted with 67% of the dose appearing in the urine. Hepatic metabolism and biliary excretion have also been demonstrated in animals (en)
|
http://linked.open.../drugbank/synonym
| - Edrophonium (en)
- EDR (en)
- Edrophonium Ion (en)
- (3-Hydroxyphenyl)dimethylethylammonium (en)
- 3-hydroxy-N,N-dimethyl-N-ethylanilinium (en)
- Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium (en)
- N-ethyl-3-hydroxy-N,N-dimethylanilinium (en)
- N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium (en)
|
http://linked.open...drugbank/toxicity
| - With drugs of this type, muscarine-like symptoms (nausea, vomiting, diarrhea, sweating, increased bronchial and salivary secretions and bradycardia) often appear with overdosage (cholinergic crisis). (en)
|
http://linked.open...umeOfDistribution
| - * 1.6±0.4 L/kg [Adults] * 2.2±1.5 L/kg [Children (0.08-10 yrs)] * 1.8±1.2 L/kg [Elderly (65-75 yrs)] (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...ogy/drugbank/salt
| |
http://linked.open...ynthesisReference
| - Terrell, R.C.; U.S. Patents 3,469,011; September 23, 1969 and 3,527,813; September 8, 1970; both assigned to Air Reduction Company, Incorporated. (en)
|
http://linked.open...y/mesh/hasConcept
| |
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| |
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...drugbank/category
| |
http://linked.open...rugbank/clearance
| - * 6.8 +/- 2. mL/kg/min [Adults] * 6.4 +/- 3.9 mL/kg/min [Children (0.08-10 yrs)] * 2.9 +/- 1.9 mL/kg/min [Elderly (65-75 yrs)] (en)
|
http://linked.open...gbank/containedIn
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |